Ultragenyx Pharmaceutical
Rare-disease biopharma selling Crysvita, Dojolvi, Evkeeza and Mepsevii with new drugs pending FDA review.
On the record
Checkpoint: FDA PDUFA decision on DTX401 for glycogen storage disease Ia
The call
Ultragenyx's approved drugs generate real, growing revenue, but 2027 profitability now rests on three unresolved FDA and trial outcomes landing within months of each other.
Ultragenyx sells prescription drugs for rare genetic diseases, with four approved medications (Crysvita, Dojolvi, Evkeeza, Mepsevii) that have exclusive rights to their markets for years, plus manufacturing expertise and detailed patient data that would take competitors a long time to rebuild. The company is hard to replace because these rare diseases have few treatment options and doctors have built relationships with Ultragenyx's existing drugs, but Ultragenyx is burning cash quickly and has already seen one drug fail testing and another rejected by regulators, so the company's survival depends entirely on whether three new drugs get FDA approval over the next year and whether the company can actually make money by 2027.
Why
01
AI pressure: None apparent. No AI product targets these ultra-rare patient populations yet; AI drug-discovery labs could someday speed rival programs but none compete here now. Could AI do the core job? Unlikely.
02
Bigger players: Ascendis Pharma (TransCon CNP for XLH). Ascendis is developing a competing hypophosphatasia/XLH therapy that could erode Crysvita's hold on Ultragenyx's largest revenue source. Could a giant copy it? No, they are blocked.
03
What protects it. Orphan-drug exclusivity, FDA approvals already in hand, and 8+ years of patient-registry data competitors cannot replicate quickly.
What would change this call
FDA decision on DTX401 by Aug 23, 2026. Approval or rejection tests whether pipeline can offset any future Crysvita/Dojolvi share erosion.
FDA decision on UX111 by Sep 19, 2026 (after July 2025 CRL). Second rejection would signal regulatory execution problems, not competitive loss.
GTX-102 Phase 3 Aspire data readout in H2 2026. Failure would remove a key growth driver meant to diversify beyond Crysvita.
FDA decision on UX111 by Sep 19, 2026 (after July 2025 CRL). Second rejection would signal regulatory execution problems, not competitive loss.
GTX-102 Phase 3 Aspire data readout in H2 2026. Failure would remove a key growth driver meant to diversify beyond Crysvita.
Key numbers
- FY2025 total revenue $673M, up 20% YoY
- Crysvita FY2025 revenue $481M, +17% YoY
- Q1 2026 revenue $136M, missed ~$158-164M consensus
Named risks
- Second FDA rejection possible for UX111 after prior July 2025 CRL, with new PDUFA Sep 19 2026.
- Three binary regulatory/clinical catalysts (DTX401, UX111, GTX-102) within 6 months determine 2027 profitability credibility.
- Cash burn of ~$575M annually against ~$738M cash reserve limits runway if launches slip.
- Q1 2026 revenue miss ($136M vs ~$158-164M consensus) signals possible demand softness in core franchises.
- Prior Phase 3 failure of setrusumab already forced a 10% workforce cut in Feb 2026.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| BioMarin Pharmaceutical | contesting | Largest rare-disease incumbent with ~47 approved drugs including Voxzogo, per May 25, 2026 analysis |
| REGENXBIO | contesting | Competing AAV programs; its RGX-121 also received an FDA CRL in Feb 2026, same regulatory environment |
| Sarepta Therapeutics | contesting | Adjacent gene-therapy incumbent facing safety controversy and share erosion as of Feb 5, 2026 |
| argenx | losing to | Signed generative-AI antibody design deal with Chai Discovery July 15, 2026, a move Ultragenyx has not matched |
Questions people ask
- Is Ultragenyx Pharmaceutical profitable in 2026?
- No. Ultragenyx posted a net loss of about $575 million for FY2025 (reported Feb 12, 2026) and continues to burn cash. The company targets profitability in 2027 following a February 2026 restructuring, contingent on new drug approvals landing on schedule.
- Did Ultragenyx have layoffs?
- Yes. On February 13, 2026, Ultragenyx cut about 130 employees, roughly 10% of its workforce, taking about $50 million in charges. The move followed a Phase 3 miss for setrusumab and was framed as part of a plan to reach profitability in 2027.
- Who is Ultragenyx Pharmaceutical's biggest competitor?
- BioMarin Pharmaceutical is the closest rare-disease incumbent, with roughly 47 approved rare disease drugs including Voxzogo and Roctavian, per a May 25, 2026 competitive landscape analysis. REGENXBIO and Sarepta also compete in adjacent AAV gene therapy programs.
- Could AI replace Ultragenyx Pharmaceutical?
- Unlikely soon. Ultragenyx's moat rests on FDA approvals, manufacturing plants, and years of patient-registry data that AI cannot shortcut. It uses DNAnexus 'Titan' for genomic analysis but had not adopted generative AI drug design as of mid-2026, unlike peer argenx's July 2026 Chai Discovery deal.
- Who owns Ultragenyx Pharmaceutical?
- Ultragenyx is a publicly traded company (NASDAQ: RARE), founded in April 2010 by Dr. Emil D. Kakkis, a former BioMarin CMO. It has no parent company; market capitalization was about $2.72 billion as of July 23, 2026, with shares near $27.04.
- Did Ultragenyx's UX111 gene therapy get FDA approved?
- Not yet as of mid-2026. The FDA issued a Complete Response Letter for UX111 in July 2025 over manufacturing issues. Ultragenyx resubmitted the BLA, which the FDA accepted on April 2, 2026, setting a new PDUFA decision date of September 19, 2026.
Timeline
- 2026-07-23Market cap about $2.72B, shares near $27.04, well below 52-week high $39.89
- 2026-05-05Q1 2026 revenue $136M, down YoY, missed consensus of $158-164M
- 2026-04-02FDA accepted UX111 BLA resubmission, new PDUFA date September 19, 2026
- 2026-02-13Cut about 130 employees (10% of workforce), ~$50M in charges after Phase 3 miss
- 2026-02-13setrusumab (UX143) Phase 3 osteogenesis imperfecta trial failed
- 2026-02-12FY2025 results: revenue $673M (+20% YoY), net loss ~$575M
- 2026-02-01FDA accepted DTX401 BLA with Priority Review, PDUFA date August 23, 2026
- 2025-07-01FDA issued Complete Response Letter for UX111 over manufacturing issues
- 2022-08-01Completed GeneTx Biotherapeutics acquisition for GTX-102/Angelman program
- 2014-01-01IPO raised approximately $126 million
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results (2026-02-12)
- Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update (2026-05-05)
- Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (2026-02-12)
- gurufocus.com (2026-07-23)
- Ultragenyx Pharmaceutical (RARE) Number of Employees (2026-06-25)
- Ultragenyx lays off 10% of workers as FDA stalls approval plan (2026-02-13)
- Rare Disease Accelerated Approval Updates (2026-03-25)
- Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111
- Ultragenyx Announces U.S. FDA Acceptance and Priority Review of DTX401 BLA
- Ultragenyx Reports First Quarter 2026 Financial Results (2026-05-05)
- More Rapid Responses to Rare Disease
- Chai Discovery Enters Into Collaboration Agreement With argenx (2026-07-15)